EXTENT: Exemestane (AROMASIN) in Combination With Sunitinib (SUTENT) in Hormone Receptor Positive Metastatic Breast Cancer.

Trial Profile

EXTENT: Exemestane (AROMASIN) in Combination With Sunitinib (SUTENT) in Hormone Receptor Positive Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Exemestane; Sunitinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms EXTENT
  • Most Recent Events

    • 25 May 2012 Primary endpoint identified as reported by ClinicalTrials.gov.
    • 25 May 2012 Actual end date Feb 2012 added as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned End Date changed from 1 Jan 2020 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top